SEC Form 4Coverage since Jun 15, 2026
$COAG insider trading
Over the last 12 months, Hemab Therapeutics Holdings insiders reported 1 buy totaling $1.7M and no sales across SEC Form 4 filings.
- Bought · 12m
- $1.7M 1 event
- Sold · 12m
- — 0 events
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $COAG · 12Mvia TradingView
Top insiders · 12m
RA CAPITAL MANAGEMENT, L.P.—1× · $1.7M
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.10% | ▲ Buy | 67,669 | $24.97 | $1.7M | +1.1% | 2 tranches · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $COAG feed.